Pulmonary Disease, Chronic Obstructive (COPD)EVALECONCT07679646
Effectiveness and Efficiency of Home Telemonitoring and Non-invasive Ventilation in Patients With COPD and Hypercapnia (EVALECO)
An observational study of Pulmonary Disease, Chronic Obstructive (COPD) and Hypercapnia, run by Air Liquide Healthcare Spain at 1 site in Spain.
Trial summary
The purpose of this study is to evaluate the effectiveness and clinical efficiency of combining home non-invasive ventilation (NIV) with a continuous remote telemonitoring (TM) system in patients with Chronic Obstructive Pulmonary Disease (COPD) and persistent hypercapnia. Read more about this study
- Who is it for?
- Ages 50 to 90 years
- Conditions the study is for
- Pulmonary Disease, Chronic Obstructive (COPD), Hypercapnia
- What is being tested?
- Home Non-Invasive Ventilation and Telemonitoring
- Type of treatment
- Medical device
- How many people
- 92 participants
- Where
- 1 siteSpain
- Study dates
- Dec 2026to Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population consists of adult patients diagnosed with severe, stable Chronic Obstructive Pulmonary Disease (COPD) and chronic persistent hypercapnia, who are managed and followed at public university hospitals within the Community of Madrid, Spain, and who have a recent history of frequent acute respiratory exacerbations.
Who may be able to join
- Age between 50 and 90 years.
- Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) according to current Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, demonstrating non-fully reversible airflow limitation with a Forced Expiratory Volume in 1 second (FEV1) < 50% of the predicted value confirmed by spirometry.
- Persistent hypercapnia, defined as PaCO2 > 53 mmHg documented for at least two weeks following an acute COPD exacerbation.
- History of two or more acute COPD exacerbations within the preceding year.
- Signed written informed consent.
Who cannot join
- Prior ongoing treatment with home non-invasive ventilation (NIV) or Continuous Positive Airway Pressure (CPAP).
- Severe obstructive sleep apnea (OSA), defined as an Apnea-Hypopnea Index (AHI) >= 30.
- Inability of the patient or the primary caregiver to comprehend or operate the telemonitoring and NIV procedures.
- Estimated life expectancy of less than one year.
- Terminal heart failure (New York Heart Association [NYHA] Class III-IV) or unstable angina.
- Advanced renal insufficiency (creatinine clearance < 30%) or inclusion in an active dialysis program.
Show all 11Show fewer
- Hepatic cirrhosis or active inclusion in a liver transplant program.
- Severe psychiatric illness requiring antipsychotic medication, active ongoing treatment for substance or alcohol addiction, or lack of a fixed home address upon hospital discharge.
- Receipt of home palliative care.
- Institutionalization.
- Classification by the attending physician as non-compliant with medical therapies, treatments, or study protocols
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Spain1 site
Hospital General Universitario Gregorio Marañón
Madrid, Madrid, 28007
Daniel López Padilla, MD, PhD, 91 586 83 28, danieleduardo.lopez@salud.madrid.org
About this study
Official title: Effectiveness and Efficiency of Home Telemonitoring and Non-invasive Ventilation in Patients With COPD and Hypercapnia
The purpose of this study is to evaluate the effectiveness and clinical efficiency of combining home non-invasive ventilation (NIV) with a continuous remote telemonitoring (TM) system in patients with Chronic Obstructive Pulmonary Disease (COPD) and persistent hypercapnia. In standard practice, patients with severe COPD and high carbon dioxide levels in their blood are treated with home non-invasive ventilation to support their breathing. This study compares two different care strategies over a one-year follow-up period:
- One group of patients will receive standard home non-invasive ventilation alone.
- Another group will receive home non-invasive ventilation combined with an automated telemonitoring system that tracks device parameters daily (such as air leaks, device usage, and breathing rates) and sends automated alerts to the healthcare team if deviations occur. The main goal of the project is to determine if adding a telemonitoring follow-up system can prevent clinical worsenings and significantly reduce the total number of days patients spend hospitalized due to severe COPD flare-ups. Additionally, the study will analyze the impact of both strategies on patients' overall health-related quality of life and the economic costs within the healthcare system.
Read the detailed description
Background and Rationale:
Chronic Obstructive Pulmonary Disease (COPD) with persistent hypercapnia is associated with increased mortality, functional decline, and high healthcare costs. While home non-invasive ventilation (NIV) is established as standard care to correct chronic respiratory failure, integrating remote telemonitoring (TM) presents an opportunity to implement early clinical interventions by allowing continuous oversight of ventilator parameters.
Study Design and Setting:
This is a prospective, multicenter, comparative cohort study with an integrated economic and utility evaluation. The study will be conducted across 5 public university hospitals within the Community of Madrid, Spain. A total of 92 patients (46 patients in the NIV+TM cohort and 46 in the conventional NIV cohort).
Study Hypotheses:
- Conceptual Hypothesis: Patients managed with the combined NIV+TM strategy experience a better clinical course than those treated with standard NIV alone.
- Statistical Hypothesis: Patients in the NIV+TM group will experience a lower average burden of exacerbation-related hospitalizations (estimated average of 24 days over 12 months) compared to the conventional NIV group (estimated average of 32 days over 12 months), reflecting a significant reduction of 8 hospital days between both management strategies during the first year of treatment.
Description of Cohorts and Follow-up Interventions:
- Combined Ventilation and Telemonitoring Cohort (NIV+TM): Patients receive standard advanced pressure-controlled nocturnal NIV combined with a remote data transmission modem. Clinical parameters-including device compliance, residual Apnea-Hypopnea Index (AHI), intentional/unintentional air leaks, respiratory rate (RR), and tidal volume (Vt)-are continuously monitored. Automated alerts are prioritized by the system: Low Priority alerts are tracked during routine visits, while High Priority alerts trigger an explicit, standardized clinical decision algorithm. This algorithm mandates immediate telephone triage, home technician visits for equipment adjustments, or direct communication with the prescribing pulmonologist for parameter adjustments. Domiciliary visits and health-related quality of life assessments (EQ-5D-5L and Severe Respiratory Insufficiency [SRI] questionnaires) will be carried out at baseline, 30, 90, 180, 270, and 365 days.
- Conventional Ventilation Cohort (NIV alone):
Patients receive identical advanced pressure-controlled nocturnal NIV settings but without remote data monitoring capabilities. Follow-up follows conventional guidelines based on standard clinical dependence: monthly home visits for patients requiring >12 hours/day of ventilation, or quarterly home visits for those requiring ≤12 hours/day. Compliance data, air leaks, and adaptation are checked manually during these visits. In-person follow-ups, EQ-5D-5L, and SRI assessments occur at baseline, day 30, and regular domiciliary visits, alongside mandatory arterial blood gas monitoring at 3, 6, and 12 months to verify treatment efficacy.
Economic and Data Analysis:
Analytical evaluations will be performed on an intention-to-treat basis. Clinical outcomes, utility values (Quality-Adjusted Life Years - QALYs gained calculated via Spanish EQ-5D-5L utility weights), and direct medical/non-medical healthcare system costs (utilizing the most recent official public tariffs from the Madrid Health Service - SERMAS) will be combined. Incremental Cost-Effectiveness Ratios (ICER), Incremental Cost-Utility Ratios (ICUR), and Incremental Cost-Benefit ratios will be constructed to evaluate healthcare efficiency. Uncertainty will be addressed via a deterministic sensitivity analysis assessing baseline, best-case, and worst-case scenarios for the telemonitoring implementation.
We have updated the Study Description to remove the term 'randomly allocated' to avoid misunderstanding. This is a strictly observational study where participants receive interventions (NIV or NIV+TM) as part of routine medical care based on institutional availability and clinical criteria, not by investigator assignment. To minimize selection bias inherent to the observational nature of the study, a consecutive sampling methodology and a post-hoc matching or adjusted statistical analysis using a block-restrictive system based on clinical variables was utilized, ensuring the investigator does not prospectively assign interventions.
- Being tested
- Home Non-Invasive Ventilation and Telemonitoring
- Keywords
- Home Noninvasive Ventilation, Telemonitoring, Respiratory Insufficiency
- Medical subject headings
- Lung Diseases, Pulmonary Disease, Chronic Obstructive, Hypercapnia, Respiratory Insufficiency
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Home Non-Invasive Ventilation and TelemonitoringDevice
Use of nocturnal home non-invasive ventilation devices equipped with or without integrated digital modems for automated parameter monitoring (compliance, leaks, residual AHI, respiratory rate, and tidal volume) over a 12-month follow-up period.
| Study group | Role | What they receive |
|---|---|---|
| NIV+TM Cohort | Patients managed with a combined strategy consisting of advanced pressure-controlled nocturnal home non-invasive ventilation (NIV) and continuous remote telemonitoring (TM). Device compliance, residual Apnea-Hypopnea Index (AHI), air leaks, respiratory rate, and tidal volume are monitored daily. High-priority automated alerts trigger a standardized clinical decision algorithm, requiring immediate telephone triage or parameter modifications. Receives: Device: Home Non-Invasive Ventilation and Telemonitoring | |
| Conventional NIV Cohort | Patients managed with conventional home non-invasive ventilation (NIV) following standard follow-up guidelines based on clinical dependence, without remote telemonitoring or automatic alert systems. Compliance and leak data are verified manually during scheduled domiciliary visits (monthly or quarterly depending on daily ventilation hours). |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of prevented days of hospitalization due to COPD acute exacerbations
The total number of days a patient spends hospitalized in a general hospital ward or Intensive Care Unit (ICU) due to acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD). An acute exacerbation is defined according to GOLD criteria as an increase in dyspnea, cough, and/or sputum worsening in less than 14 days.
Measured: 12 months
Secondary outcomes (6)
Health-Related Quality of Life and Utility (QALYs)
Measured using the validated Spanish version of the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. It evaluates 2 continuous components: the Visual Analogue Scale (VAS, scored 0-100) and the EQ-Index (scored 0-1, where 1 represents perfect health and 0 represents death). These scores will be utilized to calculate Quality-Adjusted Life Years (QALYs) gained.
Measured: Baseline, 30 days, 90 days, 180 days, 270 days, and 365 days.
Number of Acute COPD Exacerbations
Total count of localized respiratory worsening events matching the GOLD definition (worsening of dyspnea, cough, or sputum) experienced by patients during the study.
Measured: 12 months
Number of Hospital Admissions due to COPD Exacerbations
Total number of formal hospital admissions required due to severe acute respiratory deteriorations.
Measured: 12 months
Number of Emergency Department Visit
Total count of unexpected visits to hospital emergency rooms or primary care emergency facilities necessitated by acute COPD flare-ups.
Measured: 12 months
Time to first acute COPD exacerbation
The specific time period (measured in days) elapsed from the baseline treatment initiation until the documentation of the patient's first acute COPD exacerbation event.
Measured: Up to 12 months
Direct Healthcare Costs
Total direct medical and non-medical healthcare resources consumed per patient (including non-invasive ventilation service costs, telemonitoring setup, emergency visits, and hospitalization days in regular wards or ICU), calculated by applying official public healthcare tariffs from the Madrid Health Service (SERMAS).
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jul 2026
- Study startDec 2026 (estimated)
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pulmonary Disease, Chronic Obstructive (COPD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 92 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Air Liquide Healthcare Spain
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07679646
- Sponsor's protocol ID
- EVALECO-TM+VNID-EPOC
- Acronym
- EVALECO
- Status last verified
- Jun 2026
- First submitted
- 23 Jun 2026
- Last updated
- 28 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared externally due to strict patient confidentiality, data privacy, and legal regulations. In compliance with Spanish Organic Law 3/2018 (GDPR implementation) and the Patient Autonomy Law 41/2002, the link between patient identity and their study code is exclusively known and held by their attending physician\[cite: 660, 685, 690, 691\]. All clinical data collected are managed within a closed, pseudonymized centralized electronic platform (ReseaArch®) under a strict role-based access control architecture. External distribution of raw individual datasets is neither covered by the patient informed consent nor approved by the participating institutional ethics committees.
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness and Efficiency of Home Telemonitoring and Non-invasive Ventilation in Patients With COPD and Hypercapnia
- ClinicalTrials.gov ID
- NCT07679646
- Acronym / sponsor ID
- EVALECO / EVALECO-TM+VNID-EPOC
- Keywords
- Home Noninvasive Ventilation, Telemonitoring, Respiratory Insufficiency
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 92 participants (estimated)
- Lead sponsor
- Air Liquide Healthcare SpainIndustry (pharma, biotech, devices)
- Study start
- Dec 2026 (estimated)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 1 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the effectiveness and clinical efficiency of combining home non-invasive ventilation (NIV) with a continuous remote telemonitoring (TM) system in patients with Chronic Obstructive Pulmonary Disease (COPD) and persistent hypercapnia. In standard practice, patients with severe COPD and high carbon dioxide levels in their blood are treated with home non-invasive ventilation to support their breathing. This study compares two different care strategies over a one-year follow-up period:
- One group of patients will receive standard home non-invasive ventilation alone.
- Another group will receive home non-invasive ventilation combined with an automated telemonitoring system that tracks device parameters daily (such as air leaks, device usage, and breathing rates) and sends automated alerts to the healthcare team if deviations occur. The main goal of the project is to determine if adding a telemonitoring follow-up system can prevent clinical worsenings and significantly reduce the total number of days patients spend hospitalized due to severe COPD flare-ups. Additionally, the study will analyze the impact of both strategies on patients' overall health-related quality of life and the economic costs within the healthcare system.
Detailed description
Background and Rationale:
Chronic Obstructive Pulmonary Disease (COPD) with persistent hypercapnia is associated with increased mortality, functional decline, and high healthcare costs. While home non-invasive ventilation (NIV) is established as standard care to correct chronic respiratory failure, integrating remote telemonitoring (TM) presents an opportunity to implement early clinical interventions by allowing continuous oversight of ventilator parameters.
Study Design and Setting:
This is a prospective, multicenter, comparative cohort study with an integrated economic and utility evaluation. The study will be conducted across 5 public university hospitals within the Community of Madrid, Spain. A total of 92 patients (46 patients in the NIV+TM cohort and 46 in the conventional NIV cohort).
Study Hypotheses:
- Conceptual Hypothesis: Patients managed with the combined NIV+TM strategy experience a better clinical course than those treated with standard NIV alone.
- Statistical Hypothesis: Patients in the NIV+TM group will experience a lower average burden of exacerbation-related hospitalizations (estimated average of 24 days over 12 months) compared to the conventional NIV group (estimated average of 32 days over 12 months), reflecting a significant reduction of 8 hospital days between both management strategies during the first year of treatment.
Description of Cohorts and Follow-up Interventions:
- Combined Ventilation and Telemonitoring Cohort (NIV+TM): Patients receive standard advanced pressure-controlled nocturnal NIV combined with a remote data transmission modem. Clinical parameters-including device compliance, residual Apnea-Hypopnea Index (AHI), intentional/unintentional air leaks, respiratory rate (RR), and tidal volume (Vt)-are continuously monitored. Automated alerts are prioritized by the system: Low Priority alerts are tracked during routine visits, while High Priority alerts trigger an explicit, standardized clinical decision algorithm. This algorithm mandates immediate telephone triage, home technician visits for equipment adjustments, or direct communication with the prescribing pulmonologist for parameter adjustments. Domiciliary visits and health-related quality of life assessments (EQ-5D-5L and Severe Respiratory Insufficiency [SRI] questionnaires) will be carried out at baseline, 30, 90, 180, 270, and 365 days.
- Conventional Ventilation Cohort (NIV alone):
Patients receive identical advanced pressure-controlled nocturnal NIV settings but without remote data monitoring capabilities. Follow-up follows conventional guidelines based on standard clinical dependence: monthly home visits for patients requiring >12 hours/day of ventilation, or quarterly home visits for those requiring ≤12 hours/day. Compliance data, air leaks, and adaptation are checked manually during these visits. In-person follow-ups, EQ-5D-5L, and SRI assessments occur at baseline, day 30, and regular domiciliary visits, alongside mandatory arterial blood gas monitoring at 3, 6, and 12 months to verify treatment efficacy.
Economic and Data Analysis:
Analytical evaluations will be performed on an intention-to-treat basis. Clinical outcomes, utility values (Quality-Adjusted Life Years - QALYs gained calculated via Spanish EQ-5D-5L utility weights), and direct medical/non-medical healthcare system costs (utilizing the most recent official public tariffs from the Madrid Health Service - SERMAS) will be combined. Incremental Cost-Effectiveness Ratios (ICER), Incremental Cost-Utility Ratios (ICUR), and Incremental Cost-Benefit ratios will be constructed to evaluate healthcare efficiency. Uncertainty will be addressed via a deterministic sensitivity analysis assessing baseline, best-case, and worst-case scenarios for the telemonitoring implementation.
We have updated the Study Description to remove the term 'randomly allocated' to avoid misunderstanding. This is a strictly observational study where participants receive interventions (NIV or NIV+TM) as part of routine medical care based on institutional availability and clinical criteria, not by investigator assignment. To minimize selection bias inherent to the observational nature of the study, a consecutive sampling methodology and a post-hoc matching or adjusted statistical analysis using a block-restrictive system based on clinical variables was utilized, ensuring the investigator does not prospectively assign interventions.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| NIV+TM Cohort | – | Device: Home Non-Invasive Ventilation and TelemonitoringPatients managed with a combined strategy consisting of advanced pressure-controlled nocturnal home non-invasive ventilation (NIV) and continuous remote telemonitoring (TM). Device compliance, residual Apnea-Hypopnea Index (AHI), air leaks, respiratory rate, and tidal volume are monitored daily. High-priority automated alerts trigger a standardized clinical decision algorithm, requiring immediate telephone triage or parameter modifications. |
| Conventional NIV Cohort | – | –Patients managed with conventional home non-invasive ventilation (NIV) following standard follow-up guidelines based on clinical dependence, without remote telemonitoring or automatic alert systems. Compliance and leak data are verified manually during scheduled domiciliary visits (monthly or quarterly depending on daily ventilation hours). |
Who may qualify
- Ages
- 50 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population consists of adult patients diagnosed with severe, stable Chronic Obstructive Pulmonary Disease (COPD) and chronic persistent hypercapnia, who are managed and followed at public university hospitals within the Community of Madrid, Spain, and who have a recent history of frequent acute respiratory exacerbations.
Key inclusion criteria (5 listed)
- Age between 50 and 90 years.
- Confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) according to current Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, demonstrating non-fully reversible airflow limitation with a Forced Expiratory Volume in 1 second (FEV1) < 50% of the predicted value confirmed by spirometry.
- Persistent hypercapnia, defined as PaCO2 > 53 mmHg documented for at least two weeks following an acute COPD exacerbation.
- History of two or more acute COPD exacerbations within the preceding year.
- Signed written informed consent.
Key exclusion criteria (11 listed)
- Prior ongoing treatment with home non-invasive ventilation (NIV) or Continuous Positive Airway Pressure (CPAP).
- Severe obstructive sleep apnea (OSA), defined as an Apnea-Hypopnea Index (AHI) >= 30.
- Inability of the patient or the primary caregiver to comprehend or operate the telemonitoring and NIV procedures.
- Estimated life expectancy of less than one year.
- Terminal heart failure (New York Heart Association [NYHA] Class III-IV) or unstable angina.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Home Non-Invasive Ventilation and TelemonitoringUse of nocturnal home non-invasive ventilation devices equipped with or without integrated digital modems for automated parameter monitoring (compliance, leaks, residual AHI, respiratory rate, and tidal volume) over a 12-month follow-up period. | Device | NIV+TM Cohort |
Primary outcome
Number of prevented days of hospitalization due to COPD acute exacerbations
Time frame: 12 months
The total number of days a patient spends hospitalized in a general hospital ward or Intensive Care Unit (ICU) due to acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD). An acute exacerbation is defined according to GOLD criteria as an increase in dyspnea, cough, and/or sputum worsening in less than 14 days.
6 secondary outcomes
Health-Related Quality of Life and Utility (QALYs)
Time frame: Baseline, 30 days, 90 days, 180 days, 270 days, and 365 days.
Number of Acute COPD Exacerbations
Time frame: 12 months
Number of Hospital Admissions due to COPD Exacerbations
Time frame: 12 months
Number of Emergency Department Visit
Time frame: 12 months
Time to first acute COPD exacerbation
Time frame: Up to 12 months
Direct Healthcare Costs
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be shared externally due to strict patient confidentiality, data privacy, and legal regulations. In compliance with Spanish Organic Law 3/2018 (GDPR implementation) and the Patient Autonomy Law 41/2002, the link between patient identity and their study code is exclusively known and held by their attending physician[cite: 660, 685, 690, 691]. All clinical data collected are managed within a closed, pseudonymized centralized electronic platform (ReseaArch®) under a strict role-based access control architecture. External distribution of raw individual datasets is neither covered by the patient informed consent nor approved by the participating institutional ethics committees.
Related trials for Pulmonary Disease, Chronic Obstructive (COPD)
Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Active, not recruitingPhase 1
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pulmonary Disease, Chronic Obstructive (COPD) and Hypercapnia, run by Air Liquide Healthcare Spain at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 28 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Daniel López Padilla, MD, PhD (91 586 83 28, danieleduardo.lopez@salud.madrid.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of prevented days of hospitalization due to COPD acute exacerbations (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2026.